Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DECA Stock Forecast 2026-2027
$8.00
Current Price
$26.59M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DECA Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
DECA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-30.7%
1 Year Change
-46.7%
Year-to-Date Change
-65.2%
From 52W High of $23.00
+77.8%
From 52W Low of $4.50
📊 TOP ANALYST CALLS
Did DECA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Denali Capital is one of their latest high-conviction picks.
Latest DECA Stock Price Targets & Analyst Predictions
DECA has shown a year-to-date change of -46.7% and a 1-year change of -30.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for DECA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DECA Analyst Ratings
0
Buy
0
Hold
0
Sell
DECA Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $8.00
Latest DECA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DECA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Denali Capital Acquisition Corp. (DECA) Competitors
The following stocks are similar to Denali Capital based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Denali Capital Acquisition Corp. (DECA) Financial Data
Valuation Metrics
Market Cap
$26.59M
Enterprise Value
$0
P/E Ratio
71.5x
PEG Ratio
2.9x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.0%
Current Ratio
0.0x
Debt/Equity
0.0x
ROE
+12.0%
ROA
-1.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Denali Capital Acquisition Corp. (DECA) Business Model
About Denali Capital Acquisition Corp.
What They Do
Facilitates mergers and acquisitions for growth companies.
Business Model
Denali Capital Acquisition Corp. operates as a special purpose acquisition company (SPAC) that raises capital through an initial public offering (IPO) to identify and merge with growth-oriented companies. It generates revenue primarily by facilitating these mergers and helping private companies transition into publicly traded entities.
Additional Information
The company focuses on providing a streamlined pathway for private firms to go public, offering flexibility in sector focus and tapping into the increasing trend of SPAC investments in the market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3
CEO
Mr. Jaisim Shah
Country
United States
IPO Year
2022
Website
www.semnurpharma.comDenali Capital Acquisition Corp. (DECA) Latest News & Analysis
Latest News
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
1 year ago
Quick Summary
Denali Capital Acquisition Corp. extended its deadline for a business combination to July 11, 2025, by depositing $874.78 into its trust account, funded by a convertible note to Scilex Holding Company.
Why It Matters
Denali Capital's extension funding indicates ongoing efforts to finalize a business combination, impacting investor confidence and potential share value linked to the deal's success.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Denali Capital Acquisition Corp. (NASDAQ: DECA) shareholders approved an extension for completing an initial business combination until December 11, 2025, with monthly extensions possible.
Why It Matters
The extension of the business combination deadline allows Denali Capital Acquisition Corp. more time to identify and finalize a merger, potentially enhancing its investment prospects and shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Denali Capital Acquisition Corp. (NASDAQ: DECA) adjourned its Extraordinary General Meeting to April 11, 2025, to give shareholders more time to consider proposals.
Why It Matters
The adjournment of Denali Capital's shareholder meeting may signal uncertainty or significant proposals, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Semnur Pharmaceuticals will go public through a $2.5 billion merger with Denali Capital Acquisition Corp, a special purpose acquisition company.
Why It Matters
Semnur Pharmaceuticals' merger with Denali Capital at a $2.5 billion valuation signals potential growth and investment opportunities in the biotech sector, influencing market sentiment and stock performance.
Source: Reuters
Market Sentiment:
Positive
Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
2 years ago
Quick Summary
Semnur Pharmaceuticals, a subsidiary of Scilex Holding (SCLX), plans to merge with Denali Capital Acquisition Corp. (DECA) following a signed letter of intent.
Why It Matters
The proposed business combination may enhance Scilex's market position and growth potential, impacting stock performance and investor sentiment in both companies.
Source: Benzinga
Market Sentiment:
Positive
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital
2 years ago
Quick Summary
Semnur Pharmaceuticals plans to go public via a merger with Denali Capital Acquisition Corp, with the deal valued at up to $2 billion.
Why It Matters
Semnur Pharmaceuticals' merger with Denali Capital Acquisition Corp indicates potential growth and investment opportunities, potentially impacting stock performance and market interest.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About DECA Stock
What is Denali Capital Acquisition Corp.'s (DECA) stock forecast for 2027?
Analyst forecasts for Denali Capital Acquisition Corp. (DECA) are not currently available. The stock is trading at $8.00.
Is DECA stock a good investment in 2027?
Analyst ratings for DECA are not currently available. The stock is currently trading at $8.00. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DECA stock?
Price predictions from Wall Street analysts for DECA are not currently available. The stock is trading at $8.00.
What is Denali Capital Acquisition Corp.'s business model?
Denali Capital Acquisition Corp. operates as a special purpose acquisition company (SPAC) that raises capital through an initial public offering (IPO) to identify and merge with growth-oriented companies. It generates revenue primarily by facilitating these mergers and helping private companies transition into publicly traded entities.
What is the highest forecasted price for DECA Denali Capital Acquisition Corp.?
Price targets from Wall Street analysts for DECA are not currently available. The stock is trading at $8.00.
What is the lowest forecasted price for DECA Denali Capital Acquisition Corp.?
Price targets from Wall Street analysts for DECA are not currently available. The stock is trading at $8.00.
What is the overall DECA consensus from analysts for Denali Capital Acquisition Corp.?
Analyst ratings for DECA are not currently available. The stock is trading at $8.00.
How accurate are DECA stock price projections?
Stock price projections, including those for Denali Capital Acquisition Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 4:31 AM UTC